KRAS G12A
Clinical trials for KRAS G12A explained in plain language.
Never miss a new study
Get alerted when new KRAS G12A trials appear
Sign up with your email to follow new studies for KRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets common cancer mutation in first human trial
Disease control Recruiting nowThis study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check the drug's safety and find the best dose, often given with other cancer treatments. About 387 ad…
Matched conditions: KRAS G12A
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 29, 2026 01:35 UTC
-
New pill targets Hard-to-Treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-phase study tests an oral drug called S241656 in adults with advanced cancers that have specific genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrin…
Matched conditions: KRAS G12A
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC